Antibiotic teicoplanin tested for stubborn gut infection
NCT ID NCT04003818
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tested the antibiotic teicoplanin (taken by mouth twice daily for 7 to 14 days) in 50 adults hospitalized with C. difficile infection causing diarrhea and colitis. The goal was to see if it could stop diarrhea and prevent it from coming back. The trial was terminated early, so the full results are not available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Teicoplanin (an antibiotic taken by mouth)
- What this could lead to
- If successful, this could show that teicoplanin is a safe and effective option for treating C. difficile diarrhea and colitis.
- What could go wrong
- The trial was terminated early with only 50 participants planned, so results are limited. It is a phase 4 study, meaning the drug is already approved, but its effectiveness for this specific use is still being explored.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLOSTRIDIUM DIFFICILE INFECTION-ASSOCIATED DIARRHEA AND COLITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
investigational site CHINA
China, China